These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Bartoletti M; Azap O; Barac A; Bussini L; Ergonul O; Krause R; Paño-Pardo JR; Power NR; Sibani M; Szabo BG; Tsiodras S; Verweij PE; Zollner-Schwetz I; Rodríguez-Baño J Clin Microbiol Infect; 2022 Feb; 28(2):222-238. PubMed ID: 34823008 [TBL] [Abstract][Full Text] [Related]
10. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337 [TBL] [Abstract][Full Text] [Related]
12. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19. Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. Coppock D; Baram M; Chang AM; Henwood P; Kubey A; Summer R; Zurlo J; Li M; Hess B PLoS One; 2021; 16(6):e0252591. PubMed ID: 34115801 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: a retrospective analysis of a large tertiary care center in Germany. Marx K; Gončarova K; Fedders D; Kalbitz S; Kellner N; Fedders M; Lübbert C Infection; 2023 Feb; 51(1):97-108. PubMed ID: 35553032 [TBL] [Abstract][Full Text] [Related]
15. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701 [TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
17. Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. White H; McDonald SJ; Barber B; Davis J; Burr L; Nair P; Mukherjee S; Tendal B; Elliott J; McGloughlin S; Turner T Med J Aust; 2022 Oct; 217(7):368-378. PubMed ID: 36150213 [TBL] [Abstract][Full Text] [Related]